114 related articles for article (PubMed ID: 38867273)
1. Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6.
Zareinejad M; Faghih Z; Ramezani A; Safaei A; Ghaderi A
BMC Urol; 2024 Jun; 24(1):124. PubMed ID: 38867273
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
Zeng S; Liu A; Dai L; Yu X; Zhang Z; Xiong Q; Yang J; Liu F; Xu J; Xue Y; Sun Y; Xu C
BMC Cancer; 2019 Jun; 19(1):604. PubMed ID: 31216997
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line.
Ghaderi F; Ahmadvand S; Ramezani A; Montazer M; Ghaderi A
Biochem Biophys Res Commun; 2018 Oct; 505(1):181-186. PubMed ID: 30243716
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.
Russell PJ; Ow KT; Tam PN; Juarez J; Kingsley EA; Qu CF; Li Y; Cozzi PJ; Martiniello-Wilks R
Cancer Immunol Immunother; 2004 Nov; 53(11):995-1004. PubMed ID: 15449043
[TBL] [Abstract][Full Text] [Related]
6. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of the prognostic and immunological role of β-actin (ACTB) in human cancers.
Gu Y; Tang S; Wang Z; Cai L; Lian H; Shen Y; Zhou Y
Bioengineered; 2021 Dec; 12(1):6166-6185. PubMed ID: 34486492
[TBL] [Abstract][Full Text] [Related]
8. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
[TBL] [Abstract][Full Text] [Related]
9. Production of a Mouse Monoclonal Antibody Against Mortalin by Whole Cell Immunization.
Rezaei M; Ghaderi A
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):169-175. PubMed ID: 28719245
[TBL] [Abstract][Full Text] [Related]
10. Novel Monoclonal Antibodies Specific for Human Ki67 and P53 Tumor Markers in Breast Cancer Tissue Samples.
Hassanzadeh Makoui M; Mobini M; Khoshnoodi J; Bahadori T; Golsaz-Shirazi F; Moradi Tabriz H; Madjd Z; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
Iran J Immunol; 2023 May; 20(2):177-189. PubMed ID: 37149778
[TBL] [Abstract][Full Text] [Related]
11. TGF-β-induced transgelin promotes bladder cancer metastasis by regulating epithelial-mesenchymal transition and invadopodia formation.
Chen Z; He S; Zhan Y; He A; Fang D; Gong Y; Li X; Zhou L
EBioMedicine; 2019 Sep; 47():208-220. PubMed ID: 31420300
[TBL] [Abstract][Full Text] [Related]
12. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid.
Kingsley EA; Carter TE; Barrow KD; Russell PJ
Cancer Immunol Immunother; 1995 Dec; 41(6):348-54. PubMed ID: 8635192
[TBL] [Abstract][Full Text] [Related]
14. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
15. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.
Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C
Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243
[TBL] [Abstract][Full Text] [Related]
16. Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data.
Xu Y; Wu G; Li J; Li J; Ruan N; Ma L; Han X; Wei Y; Li L; Zhang H; Chen Y; Xia Q
Biomed Res Int; 2020; 2020():8283401. PubMed ID: 32047816
[TBL] [Abstract][Full Text] [Related]
17. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
18. Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer.
Gao L; Meng J; Zhang M; Fan S; Gao S; Wang X; Liang C
DNA Cell Biol; 2020 Jun; 39(6):1072-1089. PubMed ID: 32352838
[TBL] [Abstract][Full Text] [Related]
19. Knockout of
Malek N; Mrówczyńska E; Michrowska A; Mazurkiewicz E; Pavlyk I; Mazur AJ
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326615
[TBL] [Abstract][Full Text] [Related]
20. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
